ContraFect is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. The Company's most advanced product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza.